Drug Profile
Teriparatide oral - Entera Bio
Alternative Names: EB-612; EB-613; EBP-05; EP-101 - Entera Bio; hPTH(1-34); Oral hPTH(1-34); Oral PTH (1-34); oral PTH(1-34), teriparatide; Parathyroid hormone oral - Entera Bio; Parathyroid hormone-1-34 - Entera Bio; PTH oral - Entera Bio; PTH-1-34 - Entera BioLatest Information Update: 14 Mar 2024
Price :
$50
*
At a glance
- Originator Entera Bio
- Class Diagnostic agents; Osteoporosis therapies; Peptide hormones; Skin disorder therapies
- Mechanism of Action Parathyroid hormone replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Hypoparathyroidism; Osteoporosis
- Preclinical Non-union fracture
Most Recent Events
- 11 Mar 2024 Entera Bio plans a phase II trial for Fracture due to intense sport and military stress injuries (PO)
- 03 Jan 2024 Entera Bio plans a registrational pivotal phase III trial for Osteoporosis in USA (PO) in 2024
- 29 Nov 2023 Interim pharmacodynamics and pharmacokinetics data from a phase I trial in Hypoparathyroidism (In volunteers) released by Entera Bio